Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line

Cancer Research

Volumn 59, Issue 20, 1999, Pages 5133-5142

  Kimura, Akiko ^a   Ohmichi, Masahide ^a   Kurachi, Hirohisa ^a   Ikegami, Hiromasa ^a   Hayakawa, Jun ^a   Tasaka, Keiichi ^a   Kanda, Yuki ^a   Nishio, Yukihiro ^a   Jikihara, Hiroaki ^a   Matsuura, Nariaki ^b   Murata, Yuji ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CALCIUM ANTAGONIST; CISPLATIN; EGTAZIC ACID; GONADORELIN; GONADORELIN AGONIST; GONADORELIN RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; EXTRACELLULAR CALCIUM; GROWTH INHIBITION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANTINEOPLASTIC AGENTS, HORMONAL; CALCIUM; CELL DIVISION; ENZYME ACTIVATION; FEMALE; GTP-BINDING PROTEINS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LEUPROLIDE; MAP KINASE KINASE 4; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN KINASE C; PROTEINS; RECEPTORS, LHRH; RETINOBLASTOMA PROTEIN; SON OF SEVENLESS PROTEIN, DROSOPHILA; TUMOR CELLS, CULTURED;

EID: 0032723879     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (108)

1. Imai, A., Furui, T., and Tamaya, T. Is extrapituitary action of gonadotropin-releasing hormone biologically significant? Ann. Clin. Biochem., 29: 477-480, 1992.
2. Schally, A. V., Comarus-Schally, A. M., and Redding, T. W. Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc. Soc. Exp. Biol. Med., 175: 259-281, 1984.
3. Manni, A., Santen, R., Harvey, H., Lipton, A., and Max, D. Treatment of breast cancer with gonadotropin-releasing hormone. Endocr. Rev., 7: 89-113, 1986.
4. Harris, A. L., Carmichael, J., Cantwell, B. M. L., and Dowsett, M. Zolandex: endocrine and therapeutic effects in postmenopausal breast cancer. Br. J. Cancer, 59: 97-99, 1989.
5. Waxman, J. H., Harland, S. J., Coombes, R. C., Wrigley, P. F. R., Malpa, J. S., and Lister, T. A. The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother. Pharmacol., 15: 171-173, 1985.
6. Béland, G., Elhilali, M., Frader, Y., Laroche, B., Ramsey, E. W., and Trachtenberg, J. A controlled trial of castration with and without Nilutamide in metastatic prostatic carcinoma. Cancer (Phila.), 66: 1074-1079, 1990.
7. Huben, R. P., and Murphy, G. P. Investigators of the national prostatic cancer project: a comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer (Phila.), 62: 1881-1887, 1988.
8. Iversen, P., Sucius, S., Sylvester, R., Christensen, I., and Denis, L. Zolandex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. Cancer (Phila.), 66: 1067-1073, 1990.
9. Schröder, F. H. Hormonal manipulation of prostatic cancer: too soon for total androgen blockade? Br. Med. J., 303: 1489-1490, 1991.
10. Waxman, J., Man, A., Hendry, W. F., Whitfield, H. N., and Besser, G. M. Importance of early tumor exacerbation in patients treated with long acting analogues of gonadotropin releasing hormone for advanced prostatic cancer. Br. Med. J., 291: 1387-1388, 1985.
11. Gonzalez-Barcena, D., Ibarro-Olmons, M. A., Garcia-Carrasco, F., Gutierez-Samperio, C., Comarus-Schally, A. M., and Schally, A. V. Influnce of D-Trp-6-LH-RH on the survival time in patients with advanced pancreatic cancer. Biomed. Pharmacother., 43: 313-317, 1989.
12. Greenway, B. A. Carcinoma of the exocrine pancreas: a sex hormone responsive tumor? Br. J. Surg., 74: 441-442, 1987.
13. Gallagher, C. J., Oliver, R. T., Oram, D. H., Fowler, C. G., Blake, P. R., Mantell, B. S., Slevin, M. L., and Hope, Stone, H. F. A new treatment for endometrial cancer with gonadotropin releasing-hormone analogue. Br. J. Obstet. Gynaecol., 98: 1037-1041, 1991.
14. Parmar, H., Rustin, G., Lightman, S. L., Phillips, R. H., Hanham, I. W., and Schally, A. V. Response to D-Try-6-luteinizing hormone releasing hormone (Decapeptyl) microcapsules in advanced ovarian cancer. Br. Med. J. (Clin. Res. Ed.), 296: 1229, 1988.
15. Emons, G., Ortmann, O., Pahwa, G. P., Hackenberg, R., Oberheuser, F., and Schultz, K. D. Intracellular actions of gonadotropic and peptide hormones and the therapeutic value of Gn-RH agonist in ovarian cancer. Acta. Obstet. Gynecol. Scand., 71 (Suppl. 155): 31-38, 1992.
16. Eidne, K. A., Flanagan, C. A., Harris, N. S., and Millar, R. P. Gonadotropin-releasing hormone (Gn-RH)-binding sites in human breast cancer cell lines and inhibitory effects of Gn-RH antagonists. J. Clin. Endocrinol. Metab., 64: 425-432, 1987.
17. Kleinman, D., Douvdevani, A., Schally, A. V., Levy, J., and Sharoni, Y. Direct growth inhibition of human endometrial cancer cells by the gonadotropin-releasing hormone antagonist SB-75: role of apoptosis. Am. J. Obstet. Gynecol., 170: 96-102, 1994.
18. Sharoni, Y., Bosin, E., Levy, M. J., and Schally, A. V. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA, 86: 1648-1651, 1989.
19. Szende, B., Zalatnai, A., and Schally, A. V. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormones and somatostatin. Proc. Natl. Acad. Sci. USA, 86: 1613-1617, 1989.
20. Yano, T., Pinski, J., Radulovic, S., and Schally, A. V. Inhibition of human epithelial ovarian cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA, 91: 1701-1705, 1994.
21. Imai, A., Ohno, T., Iida, K., Fuseya, T., Furui, T., and Tamaya, T. Gonadotropin-releasing hormone receptor in gynecologic tumors. Cancer (Phila.), 74: 2555-2561, 1994.
22. Emons, G., Schröder, B., Ortmann, O., Westphlen, S., Schulz, K. D., and Schally, A. V. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J. Clin. Endocrinol. Metab., 77: 1458-1464, 1993.
23. Eidne, K. A., Flanagan, C. A., and Millar, R. P. Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science (Washington DC), 229: 989-991, 1985.
24. Emons, G., Ortmann, O., Becker, M., Irmer, G., Springer, B., Laun, R., Hölzel, F., Schulz, K-D., and Schally, A. V. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res., 53: 5439-5446, 1993.
25. Fekete, M., Redding, T. W., Comarus-Schally, A. M., Pontes, J. E., Connelly, R. W., Srkalovic, G., and Schally, A. V. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin and epidermal growth factor in cat and human prostate cancers and in benign prostate hyperplasia. Prostate, 14: 191-208, 1989.
26. Fekete, M., Bajusz, S., Groot, K., Csernus, V. J., and Schally, A. V. Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membrane. Endocrinology, 124: 946-955, 1989.
27. Kadar, T., Ben-David, M., Pontes, J. E., Fekete, M., and Schally, A. V. Prolactin and luteinizing hormone-releasing hormone receptors in human benign prostatic hyperplasia and prostate cancer. Prostate, 12: 299-307, 1988.
28. Liebow, C., Reilly, C., Serrano, M., and Schally, A. V. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc. Natl. Acad. Sci. USA, 86: 2003-2007, 1989.
29. 6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor in MXT mouse mammary carcinoma. Proc. Soc. Exp. Biol. Med., 192: 209-218, 1989.
30. 6]-luteinizing hormone-releasing hormone, and epidermal growth factor in human endometrial carcinoma. Cancer. Res., 50: 1841-1846, 1990.
31. Kéri, G., Balogh, A., Szöke, B., Teplán, I., and Csuka, O. Gonadotropin-releasing hormone analogues inhibit cell proliferation and activate signal transduction pathways in MDA-MB-231 human breast cancer cell line. Tumor. Biol., 12: 61-67, 1991.
32. Tsutsumi, M., Zhou, W., Millar, R. P., Mellon, P. L., Roberts, J. L., Flanagan, C. A., Dong, K., Gillo, K., and Sealfon, S. C. Cloning and functional expression of a mouse gonadotropin-releasing hormone receptor. Mol. Endocrinol., 6: 1163-1169, 1992.
33. Reinhart, J., Mertz, L. M., and Catt, K. J. Molecular cloning and expression of cDNA encoding the murine gonadotropin-releasing hormone receptors. J. Biol. Chem., 267: 21281-21284, 1992.
34. Stojilkovic, S. S., Reinhart, J., and Catt, K. J. GnRH receptors: structure and signal transduction pathways. Endocr. Rev., 15: 462-499, 1994.
35. 2+ mobilizing hormones. The case of gonadotropin-releasing hormone. Endocr. Rev., 11: 326-353, 1990.
36. Naor, Z., Shacham, S., Harris, D., Seger, R., and Reiss, N. Signal transduction of the gonadotropin releasing hormone (GnRH) receptor: cross-talk of calcium, protein kinase C (PKC) and arachidonic acid. Cell. Mol. Neurobiol., 15: 527-544, 1995.
37. Winston, B. W., Remigio, L. K., and Riches, D. W. Preferential involvement of MEK1 in the tumor necrosis factor-α-induced activation of p42mapk/erk2 in mouse macrophages. J. Biol. Chem., 270: 27391-27394, 1995.
38. Cobb, M. H., and Goldsmith, E. J. How MAP kinases are regulated. J. Biol. Chem., 270: 14843-14846, 1995.
39. Egan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland, A. M., and Weinberg, R. A. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature (Lond.), 363: 15-16, 1993.
40. Ohmichi, M., Sawada, T., Kanda, Y., Koike, K., Hirota, K., Miyake, A., and Saltiel, A. R. Thyrotropin-releasing hormone stimulates MAP kinase activity in GH3 cells by divergent pathways. J. Biol. Chem., 269; 3783-3788, 1994.
41. Ohmichi, M., Koike, K., Nohara, A., Kanda, Y., Sakamoto, Y., Zhang, Z. X., Hirota, K., and Miyake, A. Oxytocin stimulates mitogen-activated protein kinase activity in cultured human puerperal uterine myometrial cells. Endocrinology, 136: 2082-2087, 1995.
42. Ohmichi, M., Koike, K., Kimura, A., Masuhara, K., Ikegami, H., Ikebuchi, Y., Kanzaki, T., Touhara, K., Sakaue, M., Kobayashi, Y., Akabane, M., Miyake, A., and Murata, Y. The role of MAP kinase pathway in PGF2α-induced rat puerperal uterine contraction. Endocrinology, 138: 3103-3111, 1997.
43. Sawada, T., Ohmichi, M , Koike, K., Kanda, Y., Kimura, A., Masuhara, K., Ikegami, H., Inoue, M., Miyake, A., and Murata, Y. Norepinephrine stimulates mitogen-activated protein kinase activity in GT-1 GnRH neuronal cell lines. Endocrinology, 138; 5275-5281, 1997.
44. Nishida, E., and Gotoh, Y. The MAP kinase cascade is essential for diverse signal transduction pathways. Trends. Biochem. Sci., 18: 128-131, 1993.
45. Seger, R., and Krebs, E. G. The MAPK signaling cascade. FASEB J., 9: 726-735, 1995.
46. Marshal, C. J. Specificity of receptor tyrosine kinase signaling: transient vs. sustained extracellular signal-regulated kinase activation. Cell, 80: 179-185, 1995.
47. Mitchell, R., Sim, P. J., Leslie, T., and Jojnson, M. S., Thomson, F. J. Activation of MAP kinase associated with the probing effect of LHRH. J. Endocrinol., 140: R15-R18, 1994.
48. Sundaresan, S., Colin, I. M., Pestell, R. G., and Jameson, J. L. Stimulation of mitogen-activated protein kinase by gonadotropin releasing hormone: evidence for the involvement of protein kinase C. Endocrinology, 137: 304-311, 1996.
49. Reiss, N., Llevi, L. N., Shacham, S., Harris, D., Seger, R., and Naor, Z. Mechanism of mitogen-activated protein kinase activation by gonadotropin-releasing hormone in the pituitary αT3-1 cell line: differential roles of calcium and protein kinase C. Endocrinology, 138: 1673-1682, 1996.
50. Kyriakis, J. M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E. A., Ahmad, M. F., Avruch, J., and Woodgett, J. R. The stress-activated protein kinase subfamily of c-Jun kinases. Nature (Lond.), 369: 156-160, 1994.
51. Derijard, B., Hibi, M., Wu, L. H., Barrett, T., Su, B., Deng, T., Karin, M., and Davis, R. J. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell, 76: 1025-1027, 1994.
52. Minden, A., Lin, A., Claret, F.-X., Abo, A., and Karin, M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell, 81: 1147-1157, 1995.
53. Cano, E., and Mahadevan, L. C. Parallel signal processing among mammalian MAPKs. Trends Biochem. Sci., 20; 117-122, 1995.
54. Levi, N. L., Hanoch, T., Benard, O., Rozenblat, M., Harris, D., Reiss, N., Naor, Z., and Seger, R. Stimulation of Jun N-terminal kinase (JNK) by gonadotropin-releasing hormone in pituitary αT3-1 cell line is mediated by protein kinase C, c-Src, and CDC42. Mol. Endocrinology, 12: 815-824, 1998.
55. Imai, A., Takagi, H., Horibe, S., Fuseya, T., and Tamaya, T., Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors. J. Clin. Endocrinol. Metab., 81: 3249-3253, 1996.
56. Imai, A., Horibe, S., Takagi, A., and Tamaya, T. Gi protein activation of gonadotropin-releasing hormone-mediated protein dephoaphorylation in human endometrial carcinoma. Am. J. Obstet. Gynecol., 176: 371-376, 1997.
57. Cowley, S., Paterson, H., Kemp, P., and Marshall, C. J., Activation of MAP kinase kinase is necessary and sufficient for PC 12 differentiation and for transformation of NIH 3T3 cells. Cell, 77: 841-852, 1994.
58. Pages, G., Lenormand, P., L'Allemain, G., Chambard, J., Meloche, S., and Pouyssegur, J., Mitogen-activated protein kinase p42 mapk and p44 mapk are required for fibroblast proliferation. Proc. Natl. Acad. Sci. USA, 90; 8319-8323, 1993.
59. Pang, L., Sawada, T., Decker, S. J., and Saltiel, A. R., Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J. Biol. Chem., 270; 13585-13588, 1995.
60. Oehlen, B., and Cross, F. R., Signal transduction in the budding yeast Saccharomyces cerevisiae. Curr. Opin. Cell Biol., 6: 836-841, 1994.
61. Herskowitz, I. MAP kinase pathways in yeast: for mating and move. Cell, 80: 187-197, 1995.
62. Alblas, J., Slager-Davidov, R., Steenbergh, P. H., Sussenbach, J. S., and van der Burg, B. The role of MAP kinase in TPA-mediated cell cycle arrest of human breast cancer cells. Oncogene, 16: 131-139, 1998.
63. Sewing, A., Wiseman, B., Lloyd, A. C., and Land, H. High-intensity RAF signal causes cell cycle arrest mediated by p21-Cipl. Mol. Cell. Biol., 17: 5588-5597, 1997.
64. Yen, A., Roberson, M. S., Varvayanis, S., and Lee, A. T. Retinoic acid induced mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase-dependent MAP kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Cancer Res., 58: 3163-3172, 1998.
65. Laiho, M., DeCaprio, J. A., Ludlow, J. W., Livingston, D. M., and Massagué, J. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell, 62: 175-185, 1990.
66. Richon, V. M., Rifkind, R. A., and Marks, P. A. Expression and phosphorylation of the retinoblastoma protein during induced differentiation of murine erythroleukemia cells. Cell Growth Differ., 3: 413-420, 1992.
67. Hiebert, S. W., Chellappan, S. P., Horowitz, J. M., and Nevins, J. R. The interaction of RB with E2F coincides with an inhibition of the transcriptional activity of E2F. Genes Dev., 6: 177-185, 1992.
68. Weintraub, S. J., Prater, C. A., and Dean, D. C. Retinoblastoma protein switches the E2F site from positive to negative element. Nature (Lond.), 358: 259-261, 1992.
69. Akiyama, T., Ohuchi, T., Sumida, S., Matsumoto, K., and Toyoshima, K. Phosphorylation of retinoblastoma protein by cdk 2. Proc. Natl. Acad. Sci. USA, 89: 7900-7904, 1992.
70. Kato, J., Matsushima, H., Hiebert, S. W., Ewen, M. E., and Sherr, C. J. Direct binding of cyclin D to the retinoblastoma gene product (pRB) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev., 7: 331-342, 1993.
71. Zheng, C. F., Ohmichi. M., Saltiel, A. R . and Guan, K. L. Growth factor induced MEK activation is primarily mediated by an activator different from c-raf. Biochemistry, 33: 5595-5599, 1994.
72. Harris, A. N., and Mellon, P. L. The basic helix-loop-helix, leucine zipper transcription factor, USF (upstream stimulatory factor), is a key regulator of SF-1 (steroidogenic factor-1 ) gene expression in pituitary gonadotrope and steroidogenic cells. Mol. Endocrinol., 12: 714-726, 1998.
73. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
74. Chi, L., Zhou, W., Prikhozhan, A., Flanagan, C., Davidson, J. S., Golembo, M., Illing, N., m Millar, R. P., and Sealfon, S. C. Cloning and characterization of the human GnRH receptor. Mol. Cell. Endocrinol., 91: R1-6, 1993.
75. Wang, X. K., Yue, T. L., Barone, F. C., and Feuerstein, G. Z. Demonstration of increased erdothelial-leukocyte adhesion molecule-1 (ELAM-1) mRNA expression in rat ischemic cortex. Stroke, 26: 1665-1669, 1995.
76. Howe, L. R., Leevers, S. J., Gomez, N., Nakielny, S., Cohen, P., and Marshall, C. J. Activation of the MAP kinase pathway by the protein kinase raf. Cell, 71: 335-342, 1992.
77. Koch, W. J., Hawes, B. E., Allen, L. F., and Lefkowitz, R. J. Direct evidence that Gi-coupled receptor stimulation of mitogen-activated protein kinase is mediated by Gβγ activation of p21ras. Proc. Natl. Acad. Sci. USA, 91: 12706-12710, 1994.
78. Hawes, B. E., van Biesen, T., Koch, W. J., Luttrell, L. M., and Lefkowitz, R. J. Distinct pathway of Gi- and Gq-mediated Mitogen-activated protein kinase activation. J. Biol. Chem., 270: 17148-17153, 1995.
79. Ohmichi, M., Matuoka, K., Takenawa, T., and Saltiel, A. R. Growth factors differentially stimulate the phosphorylation of She proteins and their association with Grb2 in PC-12 pheochromocytoma cells. J. Biol. Chem., 269: 1143-1148, 1994.
80. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.), 227: 680-685, 1970.
81. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA, 92: 7686-7689, 1995.
82. Sanchez, I., Hugues, R. T., Mayer, B. J., Yee, K., Woodgett, J. R., Avruch, J., Kyriakis, J. M., and Zon, L. I. Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature (Lond.), 372: 794-798, 1994.
83. Dai, T., Rubie, E., Franklin, C. C , Kraft, A., Gillespie, D. A., Avruch, J., Kyriakis, J. M., and Woodgett, J. R. Stress-activated protein kinases bind directly to the δ domain of c-Jun in resting cells: implications for repression of c-Jun function. Oncogene, 10: 849-855, 1995.
84. Koch, W. J., Hawes, B. E., Allen, L. F., and Lefkowitz, R. J. Direct evidence that Gi-coupled receptor stimulation of mitogen-activated protein kinase is mediated by Gβγ activation of p21ras. Proc. Natl. Acad. Sci. USA, 91: 12706-12710, 1994.
85. Hawes, B. E., van Biesen, T., Koch, W. J., Luttrell, L. M., and Lefkowitz, R. J. Distinct pathway of Gi- and Gq-mediated mitogen-activated protein kinase activation. J. Biol. Chem., 270: 17148-17153, 1995.
86. Shimizu, Y., Tanishita, T., Minokoshi, Y., and Shimazu, T. Activation of mitogen-activated protein kinase by norepinephrine in brown adipocytes from rats. Endocrinology, 138: 248-253, 1997.
87. Sawada, T., Ohmichi, M., Koike, K., Kanda, Y., Kimura, A., Masuhara, K., Ikegami, H., Inoue, M., Miyake, A., and Murata, Y. Norepinephrine stimulates mitogen-activated protein kinase activity in GT-1 GnRH neuronal cell lines. Endocrinology, 138: 5275-5281, 1997.
88. van Biesen, T., Hawes, B. E., Luttrell, D. K., Krueger, K. M., Touhara, K., Porfiri, E., Sakaue, M., Luttrell, L. M., and Lefkowitz, R. J. Receptor-tyrosine-kinase- and Gβγ-mediated MAP kinase activation by a common signalling pathway. Nature (Lond.), 376: 781-784, 1995.
89. Pang, L., Sawada, T., Decker, S. J., and Saltiel, A. R. Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by NGF. J. Biol. Chem., 270: 13585-13588, 1996.
90. Lazar, D. F., Wiese, R. J., Brady, M. J., Mastick, C. C., Waters, S. B., Yamauchi, K., and Pessin, J. E., Cuartrecasas, P., Saltiel, A. R. Mitogen-activated protein kinase kinase inhibitor does not block the stimulation of glucose utilization by insulin. J. Biol. Chem., 270: 20801-20807, 1996.
91. Sherr, C. J. Cancer cell cycle. Science (Washington DC), 274: 1672-1677, 1996.
92. Sasaguri, T., Ishida, A., Kosaka, C., Nojima, H., and Ogata, J. Phorbol ester inhibits the phosphorylation of the retinoblastoma protein without suppressing cyclin D-associated kinase in vascular smooth muscle cells. J. Biol. Chem., 271: 8345-8351, 1996.
93. Desrivières, S., Volarevic, S., Mercep, L., and Ferrari, S. Evidence for different mechanisms of growth inhibition of T-cell lymphoma by phorbol esters and concanavalin A. J. Biol. Chem., 272: 2470-2476, 1997.
94. Pumiglia, K. M., and Decker, S. J. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. USA, 94: 448-452, 1997.
95. Thompson, M. A. Lupron retards proliferation of ovarian epithelial tumor cells cultured in serum free medium. J. Clin. Endocrinol. Metab., 72: 1036-1041, 1991.
96. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
97. 1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev., 8: 1759-1771, 1994.
98. 1-to-S transition in mammalian cell. Oncogene, 8: 1593-1602, 1993.
99. Hinds, P. W., Mittnacht, S., Dulic, V., Arnold, A., Reed, S., and Weinberg, R. A. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell, 70: 993-1006, 1992.
100. Vourel-Craviari, V., Van-Obberghen-Schilling, E., Scimeca, J. C., Van-Obberghen, E., and Pouyssegur, P. Differential activation of p44 mapk (ERK1) by α-thrombin and thrombin-receptor peptide agonist. Biochem. J., 289: 209-214, 1993.
101. Kimura, A., Ohmichi, M., Takeda, T., Kurachi, H., Ikegami, H., Koike, K., Masuhara, K., Hayakawa, J., Kanzaki, T., Kobayashi, M., Akabane, M., Inoue, M., Miyake, A., and Murata, Y. Mitogen-activated protein kinase cascade is involved in endothelin-1 -induced rat puerperal uterine contraction. Endocrinology, 140: 722-731, 1999.
102. Hawes, B. E., Luttrell, L. M., van Biesen, T., and Lefkowitz, R. J. Phosphatidylinositol 3-kinase is and early intermediate in the Gβγ-mediated mitogen-activated protein kinase signaling pathway. J. Biol. Chem., 271: 12133-12136, 1996.
103. Pang, L., Decker, S. I., and Saltiel, A. R. Bombesin and epidermal growth factor stimulate the mitogen-activated protein kinase through different pathways in Swiss 3T3 cells. Biochem. J., 289: 283-287, 1993.
104. Vahidi, H. L. R., Mischak, H., Finkenzeller, G., Marme, D., and Rapp, U. R. Protein kinase Ca activates RAF-1 by direct phosphorylation. Nature (Lend.), 364: 249-252, 1993.
105. Simonson, M. S., and Dunn, M. J. Cellular signaling by peptides of the endothelin gene family. FASEB J., 4: 2989-3000, 1990.
106. Kelly, R. A., Eid, H., Kramer, B. K., O'Neill, M., Liang, B. T., and Reers, M. Endothelin enhances the contractile responsiveness of adult rat ventricular myocytes to calcium by a pertussis toxin sensitive pathway. J. Clin. Invest., 86: 1164-1171, 1990.
107. Khac, L. D., Naze, S., and Harbon, S. Endothelin receptor type A signals both the accumulation of inositol phosphates and the inhibition of cyclic AMP generation in rat myometrium: stimulation and desensitization. Mol. Pharmacol., 46: 485-494, 1994.
108. Takuwa, Y., Kasuya, Y., Takuwa, N., Kudo, M., Yanagisawa, M., and Goto, K. Endothelin receptor is coupled to phospholipase C via a pertussis toxin insensitive guanine nucleotide binding regulatory protein in vascular smooth muscle cells. J. Clin. Invest., 85: 653-658, 1990.